The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of ovarian function as an endpoint in breast cancer clinical trials: A systematic review.
 
Wanyuan Cui
No Relationships to Disclose
 
Prudence A. Francis
Honoraria - AstraZeneca; Novartis; Novartis
Travel, Accommodations, Expenses - Ipsen; Novartis
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Martha Hickey
No Relationships to Disclose
 
Catharyn Stern
Research Funding - Ferring; Merck
 
Ann H. Partridge
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
Travel, Accommodations, Expenses - Novartis
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Cepheid (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Vifor Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)
 
Kelly-Anne Phillips
No Relationships to Disclose